MENU
GNMX
ETF ticker: BATS
PRICE
CHANGE
NET ASSETS

GNMX stock forecast, quote, news & analysis

The investment seeks capital appreciation... Show more

Category: #Health
GNMX
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for GNMX with price predictions
Oct 01, 2026

Momentum Indicator for GNMX turns positive, indicating new upward trend

GNMX saw its Momentum Indicator move above the 0 level on September 17, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 3 similar instances where the indicator turned positive. In 3 of the 3 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for GNMX just turned positive on September 21, 2026. Looking at past instances where GNMX's MACD turned positive, the stock continued to rise in 1 of 1 cases over the following month. The odds of a continued upward trend are 90%.

Following a +1.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where GNMX advanced for three days, in 8 of 8 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

The Aroon Indicator entered an Uptrend today. In 15 of 18 cases where GNMX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.

Bearish Trend Analysis

The 10-day RSI Indicator for GNMX moved out of overbought territory on October 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 4 similar instances where the indicator moved out of overbought territory. In 2 of the 4 cases, the stock moved lower in the following days. This puts the odds of a move lower at 50%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GNMX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 40%.

GNMX broke above its upper Bollinger Band on September 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Illumina (NASDAQ:ILMN), Incyte Corp (NASDAQ:INCY), Guardant Health (NASDAQ:GH), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sarepta Therapeutics (NASDAQ:SRPT).

Industry description

The investment seeks capital appreciation. The fund is an ETF that seeks to meet its objective by having Corgi Strategies, LLC actively manage the fund and, under ordinary market conditions, invest at least 80% of its net assets (plus any borrowings for investment purposes) in a portfolio of companies materially involved in the research, development, and commercialization of genomics and precision medicine technologies that enable improved disease detection, identifying and grouping patients based on genetic, molecular, or clinical characteristics to guide treatment decisions, targeted therapies, and data-driven healthcare. It is non-diversified.

Market Cap

The average market capitalization across the Corgi Genomics & Precision Medicine ETF (GNMX) ETF is 28.06B. The market cap for tickers in the group ranges from 131.87M to 250.91B. TMO holds the highest valuation in this group at 250.91B. The lowest valued company is CRBU at 131.87M.

High and low price notable news

The average weekly price growth across all stocks in the Corgi Genomics & Precision Medicine ETF (GNMX) ETF was -2%. For the same ETF, the average monthly price growth was 6%, and the average quarterly price growth was 0%. PACB experienced the highest price growth at 59%, while QURE experienced the biggest fall at -39%.

Volume

The average weekly volume growth across all stocks in the Corgi Genomics & Precision Medicine ETF (GNMX) ETF was 3%. For the same stocks of the ETF, the average monthly volume growth was 24% and the average quarterly volume growth was 13%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 59
P/E Growth Rating: 66
Price Growth Rating: 43
SMR Rating: 79
Profit Risk Rating: 86
Seasonality Score: 15 (-100 ... +100)
View a ticker or compare two or three
GNMX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a developer of therapeutic protein delivery technology

Category Health

Category
Health
Address
Corgi ETF Trust I8 THE GREEN STE B
Phone
N/A
Web
N/A
Momentum Indicator for GNMX turns positive, indicating new upward trend